Nuclear Pharmacy Services Market
完整報告名稱與涵蓋範圍
Nuclear Pharmacy Services Market Size, Share & Trends Analysis Report, By Service Type (Unit-Dose Radiopharmaceutical Compounding and Dispensing, Radioligand Therapy Dose Preparation, PET Radiopharmaceutical Distribution, Quality Control, Logistics and Waste Management Services), By Radiopharmaceutical Class (Diagnostic SPECT Agents, Diagnostic PET Agents, Therapeutic Radiopharmaceuticals), By End User (Hospitals and Nuclear Medicine Departments, Outpatient Imaging Centers, Oncology and Theranostics Clinics, Research Institutions), By Region, and Segment Forecasts, 2026-2035
報告摘要
The nuclear pharmacy services market comprises centralised and hospital-affiliated radiopharmacies that compound, quality-control, dispense and deliver patient-specific doses of diagnostic and therapeutic radiopharmaceuticals, along with associated logistics, waste handling and regulatory services. Bulk radiopharmaceutical manufacturing and isotope production are excluded, as are imaging services themselves.
Growth is being driven by the shift of nuclear medicine toward PET imaging and radioligand therapy, both of which demand short-lived agents prepared close to the point of care under tight schedules. Rising volumes of PSMA and amyloid PET, the approval of therapeutic radioligands and the expansion of theranostic clinics are widening the service mix from technetium-based unit doses to complex therapeutic dose preparation with higher activity, additional shielding and specialised training. Network operators are investing in new pharmacies, cyclotron sites and route optimisation software, while reimbursement changes for diagnostic radiopharmaceuticals in the United States and molybdenum-99 supply diversification influence margins and volumes.
The United States accounts for the largest share through national radiopharmacy chains, while Europe relies more on hospital radiopharmacies and regional networks; Japan, China, India and Australia are expanding capacity alongside new PET and theranostics centers. Competition brings together distribution-led healthcare groups, imaging-agent manufacturers with owned pharmacy networks and regional independents.
The InsightAce study provides US$ revenue forecasts for every service type, radiopharmaceutical class and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nuclear Pharmacy Services Market Snapshot
Chapter 4. Global Nuclear Pharmacy Services Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Service Type Estimates & Trend Analysis
5.1. Service Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Type:
5.2.1. Unit-Dose Radiopharmaceutical Compounding and Dispensing
5.2.2. Radioligand Therapy Dose Preparation
5.2.3. PET Radiopharmaceutical Distribution
5.2.4. Quality Control, Logistics and Waste Management Services
Chapter 6. Market Segmentation 2: By Radiopharmaceutical Class Estimates & Trend Analysis
6.1. Radiopharmaceutical Class & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Radiopharmaceutical Class:
6.2.1. Diagnostic SPECT Agents
6.2.2. Diagnostic PET Agents
6.2.3. Therapeutic Radiopharmaceuticals
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Hospitals and Nuclear Medicine Departments
7.2.2. Outpatient Imaging Centers
7.2.3. Oncology and Theranostics Clinics
7.2.4. Research Institutions
Chapter 8. Nuclear Pharmacy Services Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Cardinal Health, Inc.
10.2. Jubilant Radiopharma
10.3. PharmaLogic Holdings Corp.
10.4. Curium
10.5. GE HealthCare Technologies Inc.
10.6. Lantheus Holdings, Inc.
10.7. SOFIE Biosciences, Inc.
10.8. RLS Radiopharmacies
10.9. Siemens Healthineers (PETNET Solutions)
10.10. Alliance Medical (Life Molecular Imaging)
10.11. Eckert & Ziegler SE
10.12. Isologic Innovative Radiopharmaceuticals
10.13. Bracco Imaging S.p.A.
圖表清單 List of Tables & Figures
Table 1. Global Nuclear Pharmacy Services Revenue Forecast by Service Type, 2026-2035 (US$ Mn)
Figure 1. Global Nuclear Pharmacy Services Market Snapshot, 2026 & 2035
Table 2. Global Nuclear Pharmacy Services Revenue Forecast by Radiopharmaceutical Class, 2026-2035 (US$ Mn)
Figure 2. Global Nuclear Pharmacy Services Market Share by Radiopharmaceutical Class, 2026 & 2035
Table 3. Global Nuclear Pharmacy Services Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Nuclear Pharmacy Service Mix Shift from SPECT Unit Doses to PET and Therapeutic Doses
Table 4. North America Nuclear Pharmacy Services Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Radiopharmacy Network Density Versus Theranostics Center Growth by Region
Table 5. Europe Nuclear Pharmacy Services Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Nuclear Pharmacy Services Growth Opportunity Analysis
Table 6. Asia Pacific Nuclear Pharmacy Services Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Radiopharmaceutical Reimbursement Changes and Their Effect on Dispensing Volumes
Table 7. Latin America and Middle East & Africa Nuclear Pharmacy Services Revenue Forecast, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Nuclear Pharmacy Services Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們